ArticleCancer management and research2019

Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients.

Uzma Zaidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.